Today, let’s discuss the possibility of AI taking over cancer research, WuXi’s decision to sell some of its operations due to the BIOSECURE Act, and more exciting news in the biotech world.
AI in Cancer Research:
There is a debate on whether artificial intelligence could replace principal investigators in cancer research. While OpenAI co-founder Sam Altman believes AI could revolutionize the field, some scientists like machine learning biologist Shantanu Singh argue that AI lacks the creativity of human scientists. Singh, however, acknowledges the potential of AI in digital pathology and data processing for cancer research.
WuXi Considers Asset Sale:
Chinese drugmakers WuXi AppTec and WuXi Biologics are considering selling some of their operations in light of the BIOSECURE Act. This legislation could prohibit drugmakers with U.S. government contracts from using WuXi services. WuXi AppTec is in talks to sell its cell and gene therapy unit in Philadelphia, while WuXi Biologics is exploring the sale of its European facilities due to a drop in revenues. Despite facing challenges, WuXi may retain its assets if existing clients continue to support them.
Insight into Auditory Hallucinations in Schizophrenia:
A recent study in PLOS Biology sheds light on auditory hallucinations in schizophrenia. The research suggests that individuals with schizophrenia experience disrupted motor signals when preparing to speak, leading to misfiring signals in the brain. This discovery could pave the way for new treatment approaches for schizophrenia, potentially using non-invasive neuromodulation techniques.
President Biden’s Health Care AI Czar:
Micky Tripathi, President Biden’s health care AI czar, plays a crucial role in coordinating AI utilization across government agencies and the health care industry. This week’s episode of “The Readout LOUD” podcast delves into Tripathi’s responsibilities and the challenges he faces in his role. The podcast also covers upcoming biotech study results, a well-funded obesity company, and the latest season of “Great British Baking Show.”
In addition to these highlights, Gilead plans to donate remdesivir for emergency use against Marburg disease in Rwanda, European VC firm Kurma secures funding for biotech investments, and Opdivo receives FDA approval for lung cancer surgery.
Exciting developments continue to unfold in the biotech industry, from advancements in AI research to potential breakthroughs in schizophrenia treatment. Stay tuned for more updates on the latest innovations and discoveries shaping the future of healthcare.
